Department of Health and Human Services, through National Institutes of Health, awarded Neurogt Inc of Durham, NC $2,984,029 under the SBIR program (Phase II), with work starting 2025-09-16 and running to 2027-08-31. It is one of 2 SBIR and STTR awards Neurogt Inc received in the last two years, $3,676,678 in all. Each figure links to the federal record.
The award
| Recipient | Neurogt Inc (Durham, NC) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $2,984,029 |
| Period of performance starts | 2025-09-16 |
| Period of performance ends | 2027-08-31 |
| Award number | R44NS143501 (grant, CFDA 93.853) |
| Assistance listing | 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Place of performance | Morrisville, Wake County, NC |
| Recipient registry id (UEI) | NQHRNCAD21P3 |
Want the whole picture on Neurogt Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Neurogt Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neurogt Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Trans-bbb AAV9 gene therapy targeting cns neuropathy of mps i - project summary the goal of this Phase II SBIR project is to further develop an effective gene replacement therapy product for treating mucopolysaccharidosi
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-09-14 | Continuation | 001 | $1,484,525 |
| 2026-06-09 | Revision | 000 | $0 |
| 2026-06-09 | Revision | 000 | $0 |
| 2025-09-16 | New | 000 | $776,917 |
| 2025-09-16 | New | 000 | $722,587 |
Trans-bbb AAV9 gene therapy targeting cns neuropathy of mps i - project summary the goal of this Phase II SBIR project is to further develop an effective gene replacement therapy product for treating mucopolysaccharidosis (mps) i, towards clinical application and commercialization. Mps i is a rare lysosomal storage disease (lsd) caused by autosomal recessive defects in α-l-iduronidase (idua). The severe form of mps i (mps ih, hurler syndrome) represents the majority of known cases, with premature deaths usually before age 10 years, predominantly due to neurological impairments and cardio- respiratory failure. No effective treatment is available for neurological indications of mps ih. Because of the global diffuse neuropathy and the blood brain barrier (bbb), mps ih is not amenable to either recombinant enzyme replacement therapy (ert) or bone marrow transplantation, which are the standard of care for treating somatic symptoms of mps i. Gene replacement therapy (grt) targeting the root cause has been demonstrated to be an ideal strategy for treating monogenic diseases. Numerous studies have demonstrated success in iv or intrathecal (IT) delivery of trans-bbb-neurotropic AAV9 targeting the root cause for treating neurogenetic diseases. Importantly, the efficacy and safety profiles of iv and IT RAAV9 delivery have been demonstrated to be highly reproducible across different neurog ...
From the federal award record.
Other SBIR and STTR awards to Neurogt Inc
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-07-08 | Department of Health and Human Services | STTR Phase I | $692,649 | Novel aav gene therapy for treating cns neuropathy of mps iiic - project summary mps iiic (record) |
Every other federal award to Neurogt Inc on record
The federal register lists 4 other awards to the same registry id (UEI NQHRNCAD21P3), $6,762,650 in all, from 1 agency.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2024-09-01 | National Institutes of Health | $3,104,223 | Development of gene therapy product for treating mps iiib - project summary the goal of this fast-track SBIR p (R44NS135667) |
| 2023-08-01 | National Institutes of Health | $2,276,317 | Protein depleting pre-existing antibodies for viral gene therapy - project summary: This is a fast-track SBIR (R44AI172670) |
| 2022-08-01 | National Institutes of Health | $702,684 | Develop AAV9 gene replacement therapy for treating mps i - project summary neurogt, inc is a start-up company (R41NS127726) |
| 2020-04-15 | National Institutes of Health | $679,426 | Development of gene therapy product for treating mps iiib (R41NS115232) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Neurogt IncLook up Neurogt Inc first. Finding the company and seeing how much is on record uses no credits.
Look up Neurogt IncWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.